로딩 중…
지수 로딩 중…
Cellbion
308430· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩16,820-4.97%
2026-06-19
Price Chart
Cellbion-18.74%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 217.07B KRW |
| Revenue | 2.08B KRW |
| Net Income | -3.39B KRW |
| Total Assets | 32.38B KRW |
| Net Assets | 20.57B KRW |
| Employees | 43 |
| Value | |
| P/B | 10.55x |
| P/S | 104.46x |
| FCF Yield | -3.47% |
| Profitability | |
| ROE | -16.50% |
| ROA | -10.48% |
| Op. Margin | -434.87% |
| Revenue Growth | 27.72% |
| Financial Health | |
| Debt Ratio | 157.41% |
| Total Debt | 1.45B KRW |
| FCF | -7.53B KRW |
| Cash | 1.99B KRW |
| Current Ratio | 11.95x |
| Performance | |
| 1Y Return | -18.74% |
| 1M Return | -34.04% |
| From 52W High | -60.14% |
| 1Y MDD | -58.11% |
| Trading | |
| Volume | 68,597 shares |
| Foreign Own. | 4.03% |
| Per Share | |
| EPS | -666 KRW |
| BPS | 1,603 KRW |
Company Info
CellBion was established in 2010 with the aim of becoming a global leader in radiopharmaceuticals, and was listed on the KOSDAQ market in 2024. The company focuses on developing new anti-cancer drugs for precision medicine and targeted therapy, with Lu-177-DGUL currently under development. It produces generic specialty pharmaceuticals and operates a contract development and manufacturing organization (CDMO) business through its GMP-certified injectable vial manufacturing facility. CellBion delivers patient-specific precision anti-cancer therapy for PSMA protein-expressing prostate cancer, improving patient quality of life and advancing medical care. CellBion is headquartered in Jongno-gu, Seoul.